Prospective Comparison of (64)Copper [(64)Cu]SAR-bisPSMA vs (68)Gallium[(68)Ga] PSMA-11 PET/CT for Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy (Co-PSMA Trial)

Plain-language guide to PMID 41904043 (2026): clinical trial, phase ii study of Copper (Supplement) in 50 participants.

Key Facts

PMID: 41904043
Journal: European urology
Year: 2026
Study type: Clinical Trial, Phase II
Authors: Khan S et al. (24 authors)
DOI: 10.1016/j.eururo.2026.03.001

What This Study Did, in Plain Language

What Was Tested

Researchers studied Copper (Supplement) in this clinical trial, phase ii publication.

Prostate-specific membrane-antigen positron emission tomography (PSMA-PET) has transformed management of prostate cancer biochemical recurrence (BCR) with higher diagnostic accuracy than previous imaging modalities. 64Cu-SAR-bisPSMA PET/computed tomography (CT) (64Cu-bisPSMA) is a bivalent-PSMA-peptide with 12.7-hr half-life.

The study objective was detection rate (per-patient) comparison between 64Cu-bisPSMA and 68GaPSMA-11 PET/CT (68Ga-PSMA) in BCR post radical prostatectomy (RP) (NCT06907641).

Who Took Part

According to the abstract, 50 participants were involved.

By PubMed's age tags, the people studied were middle-aged adults and older adults, men only.

This prospective imaging trial enrolled 50 participants with BCR (PSA 0.2-0.75 ng/ml). 64Cu-bisPSMA (1 and 24 hr) and 68Ga-PSMA were acquired within 3-wk.

Management impact was evaluated after 68Ga-PSMA and 64Cu-bisPSMA.

How the Study Was Run

Images were prospectively reported, and triple read for concordance.

The primary endpoint was mean per-participant lesional difference.

Paired t tests and mixed-effects Poisson regression assessed lesion number differences between scans.

What Was Measured

Topics PubMed links to this paper include Antigens, Surface, Copper Radioisotopes, Edetic Acid, Gallium Isotopes, Gallium Radioisotopes, Kallikreins and Neoplasm Recurrence, Local.

Author keywords: (64)Cu-SAR-bisPSMA, (68)Ga-PSMA-11, Biochemical recurrence, PSMA-PET and Prostate cancer.

What This Means in Plain Language

This is a clinical trial, phase ii of Copper (Supplement) in 50 participants.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2026 (European urology), a journal based in Switzerland.

More context: the Copper (Supplement) compound page, all human trials.

Our Notes on the Compound

Copper (Supplement): The active site of cytochrome c oxidase is described as containing copper ions that are essential for electron transfer.

Copper (Supplement) in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.